Please assess the completion status of the following clinical trial:

Trial Title: Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented non-valvular AF or atrial flutter (12-lead ECG)~* Newly diagnosed or confirmed LAA thrombus in TEE (time of detection ≤ 28 days)~* Patients 18 years old~* CHA2DS2-VASc Score 1~* CrCL 30 mL/min (Cockcroft-Gault)~* Women with childbearing potential have to practice a medically accepted contraception~* Ability of patient to understand the character and the individual consequences of the clinical trial~* Signed and dated informed consent before start of any specific trial procedures~Exclusion Criteria:~* Patients \> 80 years~* Low body weight (\< 50 kg)~* Previous failure of LAA thrombus resolution with a VKA or factor Xa antagonist~* Occurrence of LAA thrombus under long-term treatment (\> 3 months) with vitamin K antagonists with an exception in the case of continued INR out of the target range~* Contraindications for oral anticoagulation therapy (see current Fachinformation for Pradaxa® (150 mg) and Marcumar® (3 mg))~* History of heart valve disorder (i.e., prosthetic valve or hemodynamically relevant valve disease)~* Valvular heart disease requiring intervention (including mechanical valves)~* Acute myocardial infarction or MI within the last 26 weeks~* Acute coronary syndrome (e.g. instable angina pectoris, STEMI, NSTEMI)~* Chronic Heart Failure (\> NYHA IIIa)~* Previous haemorrhagic stroke~* TIA within the last 90 days~* Clinical relevant bleeding within the last 26 weeks~* Acute and subacute bacterial endocarditis~* Recurrent pulmonary embolism~* Esophagitis, gastritis and gastroesophageal reflux~* Thrombocytopenia or functional platelet defects~* Congenital or acquired coagulation or haemorrhagic disorders~* Liver diseases (liver enzymes \>2 ULN)~* Renal insufficiency (CrCL below 30 mL/min)~* Pre-treatment with Dabigatran in doses higher than 110 mg bid~* Concomitant treatment with rivaroxaban, apixaban, and in case of approval during the course of the trial, also edoxaban~* Concomitant treatment with irreversible cyclooxygenase inhibitors (e.g. ASA) at doses \> 100 mg/d.~* Concomitant treatment with high doses of Adenosine diphosphate (ADP) receptor inhibitors (e.g. clopidogrel) at doses \> 75 mg/d~* Combined treatment with Adenosine diphosphate (ADP) receptor inhibitors (e.g. clopidogrel) and irreversible cyclooxygenase inhibitors (e.g. ASA) in any dose combination~* Planned treatment with long-term oral anticoagulants for alternative indications~* Concomitant treatment with P-glycoprotein (P-gp) inhibitors, i.e. verapamil.~* Need for continued treatment with ticlopidine, ticagrelor, prasugrel, systemic ketoconazole, itraconazole, posaconazole, cyclosporine, tacrolimus, dronedarone, rifampicin, phenytoin, carbamazepine, St. John's Wort or any cytotoxic/myelosuppressive therapy~* Concomitant treatment with medication not permitted~* Planned surgical intervention during expected study participation or previous surgical interventions within the last 30 days~* Other significant risk factors for bleeding complications (e.g. malignancy)~* Pregnancy and lactation.~* History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.~* Participation in other clinical trials during the present clinical trial or within the last 90 days.~* Medical or psychological condition that would not permit completion of the trial or signing of informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dabigatran (Type: EXPERIMENTAL): Dabigatran etexilate (Pradaxa®) 150 mg capsule by mouth twice daly for 3 up to 6 weeks depending on treatment response
- Phenprocoumon (Type: ACTIVE_COMPARATOR): Phenprocoumon (Marcumar®) 3 mg capsule by mouth according to INR (2-3) for 3 up to 6 weeks depending on treatment response

Based on this trial design, predict the completion outcome and termination type (if applicable).